Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SKP2 | Q13309 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | S100B | P04271 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23093076 | 0.88 | SKP2 (0.70) | SKP2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL841783 | 0.87 | SKP2 (0.73) | SKP2ALDH1A1KDM4EMAPTTDP1 | |
| SCHEMBL31634603 | 0.87 | SKP2 (0.73) | SKP2ALDH1A1KDM4EMAPTTDP1 | |
| SCHEMBL17471733 | 0.86 | SKP2 (0.68) | SKP2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL3482834 | 0.85 | SKP2 (0.70) | SKP2ALDH1A1KDM4EMAPTTDP1 | |
| SCHEMBL18353675 | 0.83 | ALDH1A1 (0.47) | SKP2ALDH1A1KDM4EALOX5GAA | |
| SCHEMBL30762210 | 0.83 | ALDH1A1 (0.47) | SKP2ALDH1A1KDM4EALOX5GAA | |
| SCHEMBL1362307 | 0.83 | SKP2 (0.57) | SKP2ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL3514830 | 0.83 | SKP2 (0.81) | SKP2ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL6692249 | 0.82 | SKP2 (0.53) | SKP2ALDH1A1KDM4EMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288552-B2 | Dihydropyridone amidesas P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-10-16 | — | — | US | claimed |
| CN-113979893-B | N-hydroxy formamidine derivative, preparation method and application | 中国药科大学 | 2023-10-24 | — | — | CN | disclosed |
| CN-113979893-A | N-hydroxyformamidine derivative, preparation method and application | 中国药科大学 | 2022-01-28 | — | — | CN | disclosed |
| US-7855205-B2 | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-21 | — | — | US | disclosed |
| US-7855205-B2 | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-21 | — | — | US | disclosed |
| US-7855205-B2 | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-21 | — | — | US | disclosed |
| EP-1764360-A1 | UREA DERIVATIVE | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
| US-20060183900-A1 | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-17 | — | — | US | disclosed |
| WO-2006050076-A1 | PYRIMIDINYL SUBSTITUTED FUSED-PYRROLYL COMPOUNDS USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183900-A1 | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders | TK1, MAP3K1, MAP3K2 | SKP2 99/4885ALDH1A1 2075/4885KDM4E 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.